Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.46 |
| ▸ | IGF1R | P08069 | 6/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15809857 | 0.93 | CDK2 (0.48) | CDK2CCNA2NTRK1IGF1RCCNE1 | |
| SCHEMBL1164753 | 0.92 | CCNA2 (0.57) | CDK2CCNA2NTRK1IGF1R | |
| SCHEMBL1165037 | 0.87 | CCNA2 (0.60) | CDK2CCNA2NTRK1IGF1R | |
| SCHEMBL12845755 | 0.86 | CDK2 (0.56) | CDK2CCNA2NTRK1IGF1RCCNE1 | |
| SCHEMBL1163953 | 0.81 | CCNA2 (0.66) | CDK2CCNA2NTRK1IGF1R | |
| SCHEMBL1164532 | 0.81 | CCNA2 (0.61) | CDK2CCNA2NTRK1IGF1R | |
| SCHEMBL12845768 | 0.80 | CCNA2 (0.59) | CDK2CCNA2NTRK1IGF1R | |
| SCHEMBL2068900 | 0.80 | CCNA2 (0.66) | CDK2CCNA2NTRK1IGF1R | |
| SCHEMBL2069637 | 0.80 | CCNA2 (0.66) | CDK2CCNA2NTRK1IGF1R | |
| SCHEMBL2069535 | 0.80 | CCNA2 (0.66) | CDK2CCNA2NTRK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422271-B2 | Pyrimidine compounds as tuberculosis inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422271-B2 | Pyrimidine compounds as tuberculosis inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2464641-B1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMA (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2464641-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2011019405-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | TYMS, TYMP, DPYD | CDK2 122/4885CCNA2 1047/4885NTRK1 4659/4885 |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | TYMS, TYMP, DPYD | CDK2 122/4885CCNA2 1047/4885NTRK1 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.